Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 201,569 shares of the specialty pharmaceutical company’s stock after selling 13,295 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.37% of Supernus Pharmaceuticals worth $7,289,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at $72,000. Venturi Wealth Management LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $92,000. KBC Group NV increased its holdings in shares of Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $211,000.

Supernus Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ SUPN opened at $31.26 on Friday. The stock has a fifty day moving average price of $36.22 and a 200 day moving average price of $35.17. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market cap of $1.74 billion, a P/E ratio of 29.22 and a beta of 0.83.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 over the last quarter. Company insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several research analyst reports. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.